- Home
- CVM vs ELEV Comparison
CVM vs ELEV Comparison
Compare CVM & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVM
- ELEV
- Stock Information
- Founded
- CVM 1983
- ELEV 2019
- Country
- CVM United States
- ELEV United States
- Employees
- CVM N/A
- ELEV N/A
- Industry
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- CVM Health Care
- ELEV Health Care
- Exchange
- CVM Nasdaq
- ELEV Nasdaq
- Market Cap
- CVM 40.1M
- ELEV 37.6M
- IPO Year
- CVM 1987
- ELEV 2021
- Fundamental
- Price
- CVM $0.62
- ELEV $0.63
- Analyst Decision
- CVM
- ELEV Strong Buy
- Analyst Count
- CVM 0
- ELEV 5
- Target Price
- CVM N/A
- ELEV $7.20
- AVG Volume (30 Days)
- CVM 469.2K
- ELEV 720.2K
- Earning Date
- CVM 02-12-2025
- ELEV 11-06-2024
- Dividend Yield
- CVM N/A
- ELEV N/A
- EPS Growth
- CVM N/A
- ELEV N/A
- EPS
- CVM N/A
- ELEV N/A
- Revenue
- CVM N/A
- ELEV N/A
- Revenue This Year
- CVM N/A
- ELEV N/A
- Revenue Next Year
- CVM $3,412.81
- ELEV N/A
- P/E Ratio
- CVM N/A
- ELEV N/A
- Revenue Growth
- CVM N/A
- ELEV N/A
- 52 Week Low
- CVM $0.49
- ELEV $0.44
- 52 Week High
- CVM $3.23
- ELEV $5.83
- Technical
- Relative Strength Index (RSI)
- CVM 45.83
- ELEV 49.52
- Support Level
- CVM $0.60
- ELEV $0.61
- Resistance Level
- CVM $0.78
- ELEV $0.70
- Average True Range (ATR)
- CVM 0.09
- ELEV 0.08
- MACD
- CVM 0.02
- ELEV 0.00
- Stochastic Oscillator
- CVM 45.66
- ELEV 25.10
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.